Objective: To identify polymorphism of Factor V Leiden and Prothrombin gene in women suffering from preeclampsia. Study design: From 142 pregnant women we identified 92 women suffering from preeclampsia and 50 healthy controls with normal pregnancy matched for age and socioeconomic status, preeclampsic patient classified as mild preeclampsia 42(45.7%) and severe preeclampsia 50(54.3%). Blood samples were tested for DNA polymorphism affecting thrombophilia Factor V Leiden and Prothrombin gene polymorphism. Results: Heterozygous AG genotype showed a significant high frequency among preeclampsic patients (20.7%) compared to controls (4.0%), (OR 6.2, P= 0.006) regarding to Prothrombin gene but: Factor V Leiden, AG genotype showed (8.7%) of preeclampsic patients which was absent in any of the controls.
Introduction:
Preeclampsia defined as pregnancyinduced protein uric hypertension with onset of clinical symptoms beyond 20 weeks gestation, it is a serious pregnancy complication and a leading cause of maternal mortality and fetal perinatal morbidity .
(1,2) Clinical disease may also be associated with abnormalities of the central nervous system, the liver, the kidneys, and intra-vascular disseminated coagulation. (3, 4, 5) Factor V Leiden (FVL) and the prothrombin gene mutations are the first and second most common genetic abnormalities associated with increased risk of deep venous thrombosis. (6) Prothrombin gene mutation is one of the most common genetic alterations associated with venous thrombosis . Thrombotic events frequently appear to result from a multifactorial process, in which acquired risk factors, such as surgery, pregnancy, trauma, immobilization, and malignancy, interact with inherited abnormalities of coagulation.
Purification Solution (Solution 1) and a DNA Elution Solution (Solution 2) along with a specially formulated purification matrix. Following removal of contaminants, the DNA was released from the matrix using DNA Elution Solution and heat. Samples of purified DNA are ready for analysis and did not require precipitation.
Polymerase chain reaction:
PCR is based on the enzymatic amplification of a fragment of DNA that is flanked by two primers (short oligonucleotide) that hybridize to the opposite strands of the target sequence and primer extention according to the complementary sequence by using enzyme DNA polymerase.
Primer sequences, PCR conditions and digestion of each polymorphism studied: Factor V Leiden G1691A and Prothrombin G20210A:
For evaluation of Factor V Leiden G1691A and Prothrombin G20210A, the following primers were used:
FV common (5`-GGA CTA CTT GAC AAT TAC TGT TCT CTT G -3`). FV WT (5`-GCA GAT CCC TGG ACA GAC G -3`). FV mutant (5`-GCA GAT CCC TGG ACA GAC A -3`). PT common (5`-TCT AGA AAC AGT TGC CTG GCA G-3`). PT WT (5`-GCA CTG GGA GCA TTG AGG ATC-3`). PT mutant (5`-GCA CTG GGA GCA TTG AGG ATT-3`). FIX-1 (5`-CTC CTG CAG CAT TGA GGG AGA TGG ACA TT-3`). FIX-2 (5`-CTC GAA TTC GGc AAG CAT ACT CAA TGT AT-3`). Factor V Leiden G1691A and prothrombin gene mutations G20210A were analyzed using a multiplex allele-specific PCR amplification .
(9,10) DNA samples extracted from peripheral blood obtained from individuals known to have factor V and prothrombin mutations were used as positive controls. The DNA extracted from all cases was also subjected to amplification of a region of factor IX gene as an internal control for assessment of the quality of the extracted DNA.
Each dNTP, 500 nmol/L of each primer, and 2. 
Statistical analysis:
All data were collected and tabulated and statistically analyzed using SPSS statistical computer package version 10 software. Quantitative variable were expressed as mean ± SD, while the qualitative variables were presented as numbers and percents. Comparison of qualitative data was done using Fisher's Exact test. Odds ratio (OR) and 95% confidence interval (95% CI) were also used to compare the frequency among study and control groups to assess risk factors. Statistical significance was set at P<0.05. 
Results

Discussion:
Preeclampsia is a common pregnancyrelated hypertension syndrome that poses a major risk of mortality and morbidity on both the woman and fetus . (11) It has been appreciated for almost 4 decades that it has a familial basis, although the exact mode of inheritance remains unclear.
The pathophysiology of preeclampsia reflects widespread dysfunction of the maternal vascular endothelium. (13) , and vascular diseases such as diabetes, essential hypertension, and anti phospholipid syndrome predispose pregnant women to preeclampsia. This, together with the marked thrombotic tendency of some women with preeclampsia . (14) ,has suggested a number of candidate genes that may be involved in the pathophysiology of preeclampsia. The risk of thrombotic events appears to be significantly higher among pregnant women with these mutations. The current study was done to identify polymorphism of Factor V Leiden and Prothrombin gene in women suffering from preeclampsia and compare between these polymorphic changes and other factors associated with preeclampsia and the implication of associated genotypes as risk factors for the development of preeclampsia. The current study revealed that prothrombin gene mutation (heterozygous/AG) was highly significant among preeclampsic patients (20.7%) compared with the controls (4.0%), (OR 6.2, P=0.006) with significance of allele A, while normal prothrombin gene genotype (GG) was found highly significant in controls. So, genotype AG may be a risk marker for preeclampsia while genotype GG may be a protective one.
Factor V Leiden mutant (heterozygous AG) was found in 8.7% of preeclampsic patients and not present in any of the controls (OR 10.1, P=0.05) with highly significant A allele, while normal genotype GG was found in 90.2% of patients and 100% of controls with significance of G allele in the controls. Multiple case-control studies found a significantly higher prevalence of Factor V Leiden in women with preeclampsia (8%-26%) compared to women with normal pregnancies (2%-10%) with OR(2-6) . (24, 25, 26, 27, 28) Among the women with history of venous thromboembolism Gerhardt et al. (29) found that the prevalence of factor V Leiden was 43.7% as compared with 7.7% among normal women, and the G20210A prothrombin gene mutation 16.9% as compared with 1.3%. On the other hand, Robert et al.
(30) and Silver et al. (31) showed that 3.8% women had the prothrombin gene mutation and they conclude that there was no association between the prothrombin G20210A mutation and pregnancy loss, preeclampsia, abruption, or SGA neonates in a low-risk, prospective cohort. Also, Stamatian et al. (32) showed that the prevalence of the Factor V Leiden mutation was higher in the control group (10.2%) as compared with the studied group (8.3%). The G20210A mutation was not isolated in any of the groups. Pregnancy complications associated with Factor V Leiden and other genetic thrombophilic mutations (e.g. Prothrombin G20210A and MTHFR C677T) are thought to be due to thrombosis of the uteroplacental vasculature.
(33,34,35) The G20210A prothrombin gene mutation and factor V Leiden individually are associated with an increased risk of venous thromboembolism during pregnancy and the puerperium, and the risk among women with both mutations is disproportionately higher than that among women with only one mutation. (29) Our results showed that Prothrombin gene mutation (homozygous/AA) was significant among women with mild preeclampsia (P=0.04) while heterozygous/AG was significant among women with severe preeclampsia (P=0.007) compared with the controls. Also, Factor V Leiden mutation (heterozygous/AG) was significant among mild preeclampsia (P=0.04) compared with the controls.
Mello et al. (28) reported that the prevalence of inherited or acquired thrombophilia was significantly higher in women with severe preeclampsia (50.7%) compared with controls (17.2%). In contrast, they found no association between thrombophilia and mild preeclampsia (16.7% Vs. 14.9% in controls). Moreover, Gerhardt et al. (36) found that women who are carriers of the G20210A Prothrombin gene mutation are at risk for early onset of severe preeclampsia. In the present study, Prothrombin gene and Factor V Leiden polymorphism showed no significant difference in genotypes in relation to age of the patient (≤24 years or >24 years), parity (primigravida or multigravida) or gestational age (≤36 week or >36 week), while Prothrombin gene mutation (AA) was significant in patients with positive family history of preeclampsia (P=0.04). A surprising finding of an Italian study is that patients with severe preeclampsia and positive thrombophilia work-up had a significantly higher rate of maternal complications such as onset of disease before 28 th week of gestation, abruptio placentae, disseminated intravascular coagulopathy, and acute renal failure compared with preeclamptic women without thrombophilia. In addition, severe preeclamptic women with thrombophilia were more likely to deliver at <28 weeks and had higher perinatal mortality compared with those without thrombophilia . (28) Our results showed that Prothrombin gene and Factor V Leiden mutations (heterozygous/AG) were significantly associated with high systolic and diastolic blood pressure (P<0.05) while normal genotype GG (both genes) was significant in control compared with hypertensive patients. So, genotypes AG of both genes may be a risk factor for severe hypertension while genotype GG of both genes may be a protective marker from severe preeclampsia. An important finding in this study is that multiple thrombophilic mutations were significantly higher in preeclamptic patients (P=0.01) while single mutation is not significant compared with the controls (P=0.5). In concordance with our results, Gerhardt et al. (29) reported that Prothrombin-gene mutation and Factor V Leiden individually are associated with an increased risk of venous thromboembolism during pregnancy and the puerperium, and the risk among women with both mutations is disproportionately higher than that among women with only one mutation.
Clearly not all women who carry a thrombophilic mutation suffer a pregnancy loss and perhaps it is those who carry multiple thrombophilic defects who are at greatest risk . (37) Thepresence of a heterozygous Factor V Leiden or heterozygous G20210A mutation in the prothrombin gene is associated with a pregnancy-associated thrombotic risk of approximately 1 in 400. Thus, in pregnant carriers of either one of these mutations the risk of venous thromboembolism is low. A combination of the two genetic risk factors can increase the risk to a modest level of 1 in 25. (38) Two small studies, from the same group of investigators, have reported that heparin thromboprophylaxis during pregnancy leads to a high live birth rate amongst women with a history of adverse pregnancy outcome and a thrombophilic defect. However, both studies were uncontrolled and the results must therefore be interpreted with caution. (39, 40) Moreover, low-molecular weight heparin was shown to improve pregnancy outcome in women with a history of one fetal loss and a constitutional thrombophilic disorder. 
References:
1-Chesley LC. 
